FDG PET (positron emission tomography) predicts osteosarcoma outcome:
This article was originally published in Clinica
Positron emission tomography (PET) may provide a powerful prognostic tool in predicting outcomes for patients with osteosarcoma, a form of bone cancer that often affects children. In a 29-patient German study, researchers found that use of PET with the radiopharmaceutical 18F-fluorodeoxyglucose (FDG) could help identify patients who have a poorer prognosis and who may be suitable for more aggressive therapy. The researchers, led by Christiane Franzius, of the University of Munster, found that the higher the initial FDG uptake in tumour, the poorer was the prognosis. Dr Franzius' study was reported at this month's Society of Nuclear Medicine meeting in Los Angeles, California. Between 500 to 1,000 new cases of osteosarcoma are estimated to occur in the US annually.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.